Approval · Notice of Compliance 38096 · 2026
NORTRIPTYLINE: Notice of Compliance 38096
Issued August 12, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 38096
- Date
- August 12, 2026
- Company
- Apotex Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Change in the composition of a dosage form. Change in the drug product manufacturing process. Change in the specification for the drug product. New package insert
- Canadian reference product
- AVENTYL (AA Pharma Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NORTRIPTYLINE | Not yet assigned | — |
Medicinal ingredients
- NORTRIPTYLINE HCL 10 MG per CAP
- NORTRIPTYLINE HCL 25 MG per CAP